Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Effect of liraglutide on body weight and microvascular function in non-diabetic overweight women with coronary microvascular dysfunction

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Carotid atherosclerosis markers and adverse cardiovascular events

    Research output: Contribution to journalLetterResearchpeer-review

  2. Cardiovascular complications in patients with total cavopulmonary connection: A nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Favorable five-year outcomes for heart failure diagnosed in younger patients without severe comorbidity

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Quality of life and the associated risk of all-cause mortality in nonischemic heart failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Long-Term Exposure to Air Pollution and Incidence of Myocardial Infarction: A Danish Nurse Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Role of fasting duration and weekday in incretin and glucose regulation

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Coronary microvascular dysfunction (CMD) is associated with adverse cardiovascular outcomes and CMD is a hallmark of type 2 diabetes. Liraglutide improves cardiovascular prognosis through partly unknown mechanisms. We hypothesized that treatment with liraglutide improves CMD and symptoms through weight loss, in non-diabetic overweight patients with angina and no obstructive coronary artery disease (CAD).

METHODS: We included 33 non-diabetic overweight women (BMI > 25) with CMD (Coronary flow velocity reserve (CFVR) ≤2.5), angina symptoms and no obstructive CAD, in an open-label proof-of-concept study. The protocol included a control period of 5 weeks followed by an intervention period with liraglutide aiming at 3 mg daily for 12 weeks. Participants were investigated before and after the control period and again 1-2 weeks after last liraglutide dose. Primary outcomes were change in CFVR and change in angina symptoms measured by the Seattle Angina Questionnaire (SAQ) in the intervention period compared with the control period. (, NCT02602600, and ethically approved).

RESULTS: Twenty-nine participants completed the study. Liraglutide treatment led to a significant weight loss (mean 6.03 kg (95%CI: 5.22;6.84)) and decrease in systolic blood pressure (mean 10.95 mm Hg (95%CI: 4.60;17.30)). Baseline median CFVR was 2.30 (IQR 1.91;2.51) and remained unchanged after liraglutide treatment (mean change 0.07 (95%CI: -0.07;0.21)). There were no effects on symptoms measured by SAQ or parameters of left ventricular systolic as well as diastolic function.

CONCLUSIONS: Treatment with liraglutide led to significant weight loss and lowering of blood pressure with no concomitant symptoms alleviation during treatment and no improvement in coronary microvascular function.

Original languageEnglish
JournalInternational Journal of Cardiology
Pages (from-to)28-34
Number of pages7
Publication statusPublished - 15 May 2019

    Research areas

  • Angina, Coronary flow velocity reserve, Coronary microvascular dysfunction, Liraglutide, Microvascular angina, Body Weight/drug effects, Overweight/complications, Echocardiography, Angina Pectoris/diagnosis, Ventricular Function, Left/drug effects, Humans, Middle Aged, Liraglutide/administration & dosage, Treatment Outcome, Hypoglycemic Agents/administration & dosage, Dose-Response Relationship, Drug, Coronary Circulation/drug effects, Female, Aged, Heart Ventricles/diagnostic imaging, Coronary Vessels/diagnostic imaging, Microcirculation/drug effects

ID: 56740416